Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Therapeutic cancer treatments often focus on antiproliferation, but cell differentiation offers a promising alternative.
• Acute myeloid leukemia (AML) exhibits differentiation arrest, making Cyclin-dependent kinase 2 (CDK2) inactivation a potential therapeutic strategy.
• Existing treatments lack selective CDK2 inhibitors, and inhibiting its enzymatic function alone is insufficient for significant AML differentiation.

Purpose of the Study:

• To develop a chemical tool for validating the role and druggability of CDK2 in AML differentiation.
• To create first-in-class CDK2-targeted proteolysis-targeting chimeras (PROTACs).

Main Methods:

• Development of novel CDK2-targeted PROTACs.
• Assessment of PROTACs' efficacy in degrading CDK2 in various cell lines.
• Evaluation of PROTACs' impact on AML cell line and primary patient cell differentiation.

Main Results:

• The developed PROTACs achieved rapid and potent degradation of CDK2.
• CDK2 degradation was specific, with no significant degradation of other cellular targets.
• PROTACs induced remarkable differentiation in AML cell lines and primary patient cells.

Conclusions:

• CDK2-targeted PROTACs are effective tools for promoting AML cell differentiation.
• PROTACs represent a practical and important alternative for verifying CDK2 protein functions.
• This study highlights the potential of PROTACs in cancer therapy research.